type in your search and press enter
You May Also Like
Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results
– Phase 3 VISION Trial Design Finalized for 177Lu-PSMA-617 Following Successful End of Phase ...
Tyme Inc. Appoints Dr. Jonathan Eckard as Chief Scientific Affairs Officer
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical ...
Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
New evidence supporting the benefit of selective BET inhibition in the treatment of cardiovascular ...